The outcome of short-term low-dose aspirin treatment in Kawasaki disease based on inflammatory markers.
- Author:
Jae Won YOO
1
;
Ji Mok KIM
;
Hong Ryang KIL
Author Information
- Publication Type:Original Article
- Keywords: Kawasaki disease; Inflammation; Aspirin
- MeSH: Aspirin*; Blood Cell Count; Blood Sedimentation; Chungcheongnam-do; Coronary Vessels; Echocardiography; Fever; Follow-Up Studies; Humans; Inflammation; Medical Records; Mucocutaneous Lymph Node Syndrome*; Retrospective Studies
- From:Korean Journal of Pediatrics 2017;60(1):24-29
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Previously, Kawasaki disease (KD) treatment with low-dose aspirin was administered for 6–8 weeks after the acute phase. However, inflammatory marker levels normalize before 6–8 weeks. In this study, we aimed to investigate the clinical outcome of short-term low-dose aspirin treatment based on inflammatory and thrombotic marker levels. METHODS: We performed a retrospective review of the medical records of patients with KD who were hospitalized at Chungnam National University Hospital between September 2012 and May 2014. When fever subsided, low-dose aspirin treatment was started. Inflammatory (white blood cell count, erythrocyte sedimentation rate, and C-reactive protein) and thrombotic markers (D-dimer) were monitored at follow-ups conducted in 1- to 2-week intervals. The low-dose aspirin administration was terminated when both markers were normalized and no cardiovascular complications were observed. RESULTS: Eighty-four patients with KD (complete KD, n=49; incomplete KD, n=35) were enrolled. The inflammatory and thrombotic marker levels were normalized within 3–4 weeks on average. At the beginning the low-dose aspirin treatment, 9 patients had coronary artery lesions but 75 did not. When the low-dose aspirin administration was terminated at the time the inflammatory marker levels were normalized, no new CALs developed during the follow-up at 6–8 weeks. CONCLUSION: Most of the inflammatory marker levels were normalized within 3–4 weeks after the acute phase of KD. New cardiovascular complications did not develop during the course of the short-term aspirin treatment based on the inflammatory marker levels, clinical findings, and echocardiography.
